250 related articles for article (PubMed ID: 21290089)
1. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses.
Negoro E; Yamauchi T; Urasaki Y; Nishi R; Hori H; Ueda T
Int J Oncol; 2011 Apr; 38(4):911-9. PubMed ID: 21290089
[TBL] [Abstract][Full Text] [Related]
2. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.
Grant S; Turner A; Nelms P; Yanovich S
Leukemia; 1995 May; 9(5):808-14. PubMed ID: 7769843
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Bhalla K; Nayak R; Grant S
Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
[TBL] [Abstract][Full Text] [Related]
5. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
[TBL] [Abstract][Full Text] [Related]
6. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
8. Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-derived cells.
Takagaki K; Katsuma S; Kaminishi Y; Horio T; Nakagawa S; Tanaka T; Ohgi T; Yano J
J Biochem; 2004 Nov; 136(5):733-40. PubMed ID: 15632314
[TBL] [Abstract][Full Text] [Related]
9. Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells.
Kanno S; Hiura T; Ohtake T; Koiwai K; Suzuki H; Ujibe M; Ishikawa M
Clin Chim Acta; 2007 Feb; 377(1-2):144-9. PubMed ID: 17097625
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
Bergman AM; Kuiper CM; Voorn DA; Comijn EM; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
Biochem Pharmacol; 2004 Feb; 67(3):503-11. PubMed ID: 15037202
[TBL] [Abstract][Full Text] [Related]
11. Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67).
Grant S; Freemerman AJ; Birrer MJ; Martin HA; Turner AJ; Szabo E; Chelliah J; Jarvis WD
Cell Growth Differ; 1996 May; 7(5):603-13. PubMed ID: 8732670
[TBL] [Abstract][Full Text] [Related]
12. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
Yamamoto S; Yamauchi T; Kawai Y; Takemura H; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Int J Hematol; 2007 Feb; 85(2):108-15. PubMed ID: 17321987
[TBL] [Abstract][Full Text] [Related]
14. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
[TBL] [Abstract][Full Text] [Related]
15. Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines.
Rathe SK; Largaespada DA
Leukemia; 2010 Aug; 24(8):1513-5. PubMed ID: 20508618
[No Abstract] [Full Text] [Related]
16. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
Majlessipour F; Avramis IA; Kwock R; Weinberg KI; Avrami VI
Anticancer Res; 2002; 22(3):1361-8. PubMed ID: 12168812
[TBL] [Abstract][Full Text] [Related]
17. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells.
Cai J; Damaraju VL; Groulx N; Mowles D; Peng Y; Robins MJ; Cass CE; Gros P
Cancer Res; 2008 Apr; 68(7):2349-57. PubMed ID: 18381442
[TBL] [Abstract][Full Text] [Related]
18. Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
Anticancer Res; 2014 Apr; 34(4):1657-62. PubMed ID: 24692694
[TBL] [Abstract][Full Text] [Related]
19. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
Kong XB; Tong WP; Chou TC
Mol Pharmacol; 1991 Feb; 39(2):250-7. PubMed ID: 1705001
[TBL] [Abstract][Full Text] [Related]
20. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
Ramilo-Torno LV; Avramis VI
Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
